The macrophage theory of depression proposes that abnormal secretions of the macrophage cytokines, an increase in interleukin (IL) 1, and a decrease in IL-2 may cause depression. The olfactory bulbectomized (OB) rat has been developed as an animal model of depression. In the present study, the effects of intracerebroventricular administration of IL-2 (10 U) for 7 days on behaviour, neurotransmitter concentrations, corticosterone levels, and some immune functions were investigated. In the novel environment of the ''open-field'' apparatus, the OB rat showed increases in ambulation, rearing, grooming, and defaecation scores as compared with sham-operated animals. Following IL-2 administration, grooming and defaecation were significantly attenuated, while the ambulation and rearing scores were unaffected. In the elevated plus-maze, the increase in the time spent on the open arms of the maze by the OB animal was normalized by IL-2 administration. In the brain of untreated OB rats, the concentrations of noradrenaline were reduced; IL-2 treatment significantly increased the concentrations of noradrenaline and serotonin. After administration of IL-2 for 7 days, the impairments in the immune functions were also largely reversed in OB rats. Thus IL-2 significantly normalized the hyperactivity of mononuclear cells, the suppression of lymphocyte proliferation, and the reduction in the monocyte percentage in the white blood cell count in the OB rat. The concentrations of corticosterone in the serum of the OB rat were significantly reduced, but returned to control values following IL-2 treatment. The results suggest that IL-2 may have modulatory functions on behavioural, neurochemical, hormonal, and immunological aspects of the OB rat model of depression.

Keywords:
Macrophage, Interleukin-2, Depression, Olfactory bulbectomy, Neuroimmunomodulation
This content is only available via PDF.
© 1995 S. Karger AG, Basel
1996
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.